Gossamer Bio, Inc. (GOSS): Cash & Equivalents
$37.73M
As of 2025-12-31
$41.15M
As of 2026-06-30
-30.4%
3-year compound annual growth
-40.0%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.73M | -18.1% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $46.07M | +43.5% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $32.11M | -71.3% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $111.97M | -38.9% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $183.40M | -62.3% | 2023-03-17, Balance as of period end |
| 2020-12-31 | $486.06M | +260.0% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $135.03M | +28.3% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $105.22M | n/a | 2020-03-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $37.73M | -18.1% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $34.33M | -48.5% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $128.39M | +32.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $120.72M | -49.3% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $737.06M | +88.0% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $11.44M | -36.3% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $4.47M | +23.7% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $137.53M | +148.7% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $48.30M | -38.1% |
Compare GOSS, LXRX, PTGX, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗